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In spite of the extreme rise to the knowledge of nanotechnology in pharmaceutical sciences, there are currently
limited experimental works studying the interactions between nanoparticles (NPs) and the biological system.
Adjustment of size and surface area plays the main role in the reaction between NPs and cells leading to their
increased entrance into cells through skin, gastrointestinal and respiratory system. Moreover, change in
physicochemical reactivity of NPs causes them to interact with circulatory and cellular proteins differentially leading
to the altered parameters of their biokinetics, including adsorption, distribution, translocation, transformation, and
elimination. A direct relationship between the surface area, reactive oxygen species generating capability, and
proinflammatory effects of NPs have been found in respiratory tract toxicity. Additionally, complement-mediated
hypersensitivity reactions to liposomes and other lipid-based nanodrugs have been well defined. Inhalation studies
of some NPs have confirmed the translocation of inhaled materials to extra pulmonary organs such as central
nervous system (CNS) via olfactory neurons and induction of inflammatory response. Injectable uncoated NPs have
a tendency to remain on the injection site while the poly ethanol glycol (PEG)-coated NPs can be notably drained
from the injection site to get as far as the lymph nodes where they accumulate. This confirms the existence of
channels within the extracellular matrix for NPs to move along. Furthermore, induction of DNA strand breaks and
formation of micronuclei have been recorded for exposure to some NPs such as single-walled carbon nanotubes.
In the recent years, most of the studies have simply outlined better efficacy of nanodrugs, but few discussed their
possible toxic reactions specially if used chronically. Therefore, we emphasize that this part of the nanoscience must
not be undermined and toxicologists must be sensitive to set up suitable in vivo or in vitro toxicity models. A
system for collecting data about the relationships between NPs’ structure-size-efficacy-toxicity (SSET) should be
specified with special regard to portal of entry and target organ.
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Nanotechnology is a multidisciplinary area, which uti-
lizes knowledge from the fields of physics, chemistry,
biology, medicine, material's science and engineering.
New perspectives in medical sciences have been de-
veloped by the growth of nanotechnology in the last few
decades so that nanoparticles (NPs) are expected to
hold a key position in various parts such as diagnosis,
imaging, and particularly, drug delivery. Even though,
the biotechnology has made different potent pharma-
ceutics, some of these products face problems in* Correspondence: Mohammad.Abdollahi@UToronto.Ca
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distribution, and reproduction in any mediumbiological systems. Modern nanotechnology provides
new methods to achieve temporal and spatial site-
specific delivery [1].
The term of NP is defined with regard to the size of
particle. For material scientists, NPs are with the size of
~100 nm while for atmospherical scientists, the nucle-
ation mode (<10 nm) of the atmospherical multimodal
size distribution is often referred to NP. Furthermore,
medical scientists define all particles below 1000 nm as
NP. The fact that information on size characteristics is
not always provided in publications causes confusion
while search for NPs in published works is done. How-
ever, the particles with the sizes smaller than 100 nm is
suggested to be considered as NPs in pharmaceutical
studies [2].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pending upon their chemical composition (purity, crystal-
line and electronic properties), small size (surface area and
size distribution), surface structure (surface reactivity, sur-
face groups, inorganic and organic coatings), solubility,
shape, and aggregation. In the biological system, these
properties of NPs have a significant impact on their cellu-
lar uptake, protein binding, translocation from way of
entry into the target site and the possibility of tissue injury
so that concerns over their adverse effects have been raised
recently [3]. For instance, complement-mediated hyper-
sensitivity reactions to liposomes and other lipid-based
nanodrugs by the classical or the mannose-binding lectin
pathway or the alternative pathway have been recognized
that necessitates special attention of toxicologists to
emerge establishment of specific toxicity tests [4].
In the present article, we have focused on the kinetics of
NPs and their potential interactions with fluids, cells,
tissues via a range of possible pathways towards target
organs. All nanomedicinal products must undergo special
safety tests in order to ensure they do not cause any po-
tential hazard. Although, environmental accumulation and
degradation of these compounds are important to be
evaluated, that is beyond the scope of the present review.
To avoid testing in several species of animals, information
gathered on metabolism, pharmacokinetics, and toxicol-
ogy would end up in cost benefit tests.
Biokinetics of NPs
The main characteristic of NPs is their size, which can
modify the physicochemical properties of the material
and create a different biokinetics which can lead to oc-
currence of toxic effects at nontoxic doses. In this way,
understanding biokinetics of NPs can provide informa-
tion on the amount of doses reaching body organs, in
comparison with the non-NP form of own materials.
Furthermore, NPs’ biokinetics is important for manipu-
lating in vitro studies since it helps to determine sensi-
tive target organs and explain the selection of NP
concentrations in cell culture media, while studying
effects and mechanisms in cells of a specific target
organ. According to previous studies, biokinetics and
toxicity of NPs depend on particle size, aggregation shape,
chemical composition or crystal structure, surface area,
surface chemistry, surface charge, surface composition, sta-
bility, solubility, and the rate of material release during dis-
solution [5].
From a toxicological attitude, particle size and surface
area are important characteristics for NPs. Smaller size
can create the opportunity for increased uptake and inter-
action with different parts of biological system. In the
circulation, NPs are mainly taken up by mononuclear
phagocytic cells acting as a depot and defense mechanism.
The rate of this uptake is a determinant factor for thehalf-life of NPs in the blood. Some circulatory proteins
like opsonins bind NPs in the blood and increase the rate
of phagocytosis. In fact, opsonization assists the NPs to
attach the superficial part of phagocytic cells, particularly
monocytes, macrophages, neutrophils and dendritic cells
via particular receptors. Solubility is a key factor in opso-
nization so that hydrophobic NPs tend to be easily
attached rather than hydrophilic and neutral ones. Dis-
similar to this condition, coating with hydrophilic
polymers such as polyethylene glycol (PEG) counteracts
with opsonization, which permits NPs to stay in the circu-
lation for much longer periods and carried throughout the
body to reach most of the tissues and cells [6].
Vascular endothelium with tight junctions is the next
barrier for passage of NPs into the cells. Brain endothelial
junctions are mainly close-fitting and effectual but in
some specialized tissue such as liver, the endothelium is
perforated and lets particles up to 100 nm to pass and go
in the critical parenchymal cells. In spleen, the endothe-
lium is inconsistent and contains greater fenestrations
even without basement membrane, which allows very
large particles to pass. Of course, in certain inflammatory
conditions, the endothelium becomes more permeable
even to bigger particles. Still, particles can pass through
the cells by pinocytosis. Although the small size may be
favorable for a rapid entry into the cells, no size cut off
limit up to at least 5 μm can be estimated for pinocytosis.
A major problem in dismembering the special effects of
the size is high polydispersity of various NPs that seems
dependent on the chemical structure [7].
Distribution of NPs into the organs is mainly done in
liver followed by spleen, lymph node, and bone marrow.
Some NPs can cross blood–brain barrier (BBB), an uptake
which can be more facilitated by negative surface charge
and binding to proteins such as albumin, Apo, and im-
munoglobulin G. NPs are found to be eliminated via urine
or bile excretion in unmetabolized form, though there is
some evidence on their metabolism [5]. Extra entrance
through BBB not only is undesirable in some cases but
may initiate serious side effects and toxicity.
However, the interaction between NPs and proteins
plays the main role in their connections, distribution,
transformation, accumulation, and clearance in the body.
These interactions are mainly related to the corporeal
form and chemical composition of NPs. For instance, im-
plicating on scavenger-related elimination; NPs are likely
to have a restricted distribution, while it has been evident
that physical and chemical changes in NPs’ nature consid-
erably influence their distribution [8].
Furthermore, decreased size and increased surface area
can lead to the more atoms or molecules to be exposed to
the surface rather than the interior of the material. In fact,
the number of atoms or molecules at the surface of the
particle can define the material reactivity and biological
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Altered biokinetics as a source of NPs toxicity
The result of some studies have shown that change in
physicochemical properties of NPs due to their decreased
size and increased surface area can create a series of toxic
effects. For instance, in the lung, a direct relationship
between the surface area, reactive oxygen species (ROS)-
generating capability, and proinflammatory effects of NPs
has been found. Additionally, studies show that the small
size and large surface area of NPs increase their ability to
induce lung injury [9].
Pulmonary and cardiovascular effects have been mostly
attributed to inhalation exposure to smaller particles.
Nevertheless, the evidence on how well particles can cross
particular tissues outside the circulation is more sparse.
Inhalation studies of some NPs have confirmed the trans-
location of inhaled materials to extra pulmonary organs. It
has been shown that following nasal application, inhaled
NPs can even get access to the central nervous system
(CNS) via olfactory neurons and substantially fire the
inflammatory response [10].
A comparison between some effects of NPs (<100 nm)
and larger particles (>500 nm), when they are taken up via
the respiratory tract was described by Oberdörster [11].
Regarding respiratory tract as portal of entry, it was
recognized that “translocation to secondary organs,
lymphatic circulation, uptake and transport by sensory
neurons, protein/lipid adsorption, entry to cells, entry to
mitochondria, entry to nucleus, direct effect on the portal
of entry and on the secondary organs” are among the
characteristics that seen in NPs smaller than 100 nm
whereas particles larger than 500 nm, only produced dir-
ect effect on the portal of entry.
The injected NPs into the extracellular matrix can get
back to the circulation by drainage of lymphatic vessels
and lymph nodes [12]. Although uncoated NPs have a
tendency to remain near the injection site, the poly etha-
nol glycol (PEG) coated NPs can be conspiciously
drained away from the injection site. Coating’s thickness
is an important factor as thin coatings cause NPs to get
as far as the lymph nodes where they can accumulate. In
thicker coating, they can depart from the lymph nodes
and get back to the circulation. This supports the idea of
existence of channels within the extracellular matrix for
NPs to move along [13]. Once and for all, induction of
DNA strand breaks and formation of micronuclei have
been preserved for exposure to some NPs such as
single-walled carbon nanotubes [14].
Conclusion
The link between specific kinetics and induction of tox-
icity is now a well-known fact and not hidden but feelsundermined for nanodrugs. Apart from that, nanodrugs
are able to pass through different cellular barriers much
more than that of usual drugs; their biologic behavior is
under influence of synergistic interaction between physical
and chemical characteristics. In the recent years, most of
the studies have simply outlined slightly better efficacy of
nanodrugs, but few discussed their possible toxic reactions
specially if used chronically. Therefore, we emphasize that
this part of the nanoscience must be re-considered and
toxicologists must be sensitive to set up suitable in vivo
and in vitro toxicity models. This means that each new
nanodrug must undergo full toxicity tests even if its non-
nano form has been already used and found safe. In this
respect, it is reasonable to mention that most of the tox-
icity studies for nanodrugs in the recent years have been
conducted in vitro. The limitation of such in vitro models
is that most of them are conducted on the neoplastic
passaged cell lines. Such results are under question since
the function and responses of such cell lines are not fully
similar to that of normal fresh cells [15]. Therefore, for ef-
ficacy and safety evaluation of nanodrugs, a method based
on an approved animal model or an appropriate primary
normal cell culture is assertively recommended. This so
important task should be paid proper attention to com-
pletely fulfill the criteria to prove safety of nanodrugs.
Additionally, since some nanodrugs are currently in thera-
peutic use, collection of adverse reaction and toxicity
reports from the community will help health professionals
and regulatory organisations to decide about their safety
and usage. A system for collecting data about the
relationships between NPs’ structure-size-efficacy-toxicity
(SSET) should be specified with special regard to portal of
entry and target organ.
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